Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis

Chaohua Deng; Arnaud Bianchi; Nathalie Presle; David Moulin; Meriem Koufany; Cécile Guillaume; Hervé Kempf; Anne Pizard

doi:10.1136/annrheumdis-2016-210700

Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis

Ann Rheum Dis. 2018 Feb;77(2):315-316. doi: 10.1136/annrheumdis-2016-210700. Epub 2017 May 5.

Authors

Chaohua Deng^{1

2}, Arnaud Bianchi^{1

2}, Nathalie Presle^{1

2}, David Moulin^{1

2

3}, Meriem Koufany^{1

2}, Cécile Guillaume^{1

2}, Hervé Kempf^{1

2}, Anne Pizard^{2

3

4

5}

Affiliations

¹ UMR7365 CNRS-Université de Lorraine, IMoPA, Ingénierie Moléculaire et Physiopathologie Articulaire, Vandoeuvre-les-Nancy, France.
² Fédération de Recherche 3209, Vandoeuvre-les-Nancy, France.
³ CHRU Nancy, Vandoeuvre-les-Nancy, France.
⁴ CIC-P1433 Inserm, CHRU Nancy, Vandoeuvre-les-Nancy, France.
⁵ UMRS-Inserm U1116, Université de Lorraine, Vandoeuvre-les-Nancy, France.

PMID: 28476879
DOI: 10.1136/annrheumdis-2016-210700

No abstract available

Keywords: DMARDs (synthetic); osteoarthritis; treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Disease Models, Animal
Eplerenone / pharmacology*
Metabolic Syndrome / complications*
Metabolic Syndrome / drug therapy
Mineralocorticoid Receptor Antagonists / pharmacology*
Osteoarthritis / drug therapy*
Osteoarthritis / etiology
Rats

Substances

Mineralocorticoid Receptor Antagonists
Eplerenone